Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients

Kynast, B.; Binder, Lutz; Marx, D; Zoll, Barbara; Schmoll, H.-J.; Oellerich, Michael; Schauer, A.

doi:10.1007/bf01212719

Cited by 34 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with that found in the few studies that have examined overexpression in MBC; ie 20-57% of patients with MBC have elevated HER-2 plasma concentrations. [14][15][16][17][18][19][20][22][23][24][25] The HER-2 positive patients in this study had a significantly decreased OS and PFS following HDCT and ABSC transplantation ( Table 2 and Figures 1 and 2). Therefore, the presence of elevated plasma HER-2 may be an important prognostic factor that could be used to select more effective and additional therapies for these patients (eg directly targeted treatments using immunologic therapy).…”

Section: Discussionmentioning

confidence: 66%

“…[7][8][9][10][11][12][13][14] Although HER-2 oncoprotein overexpression correlates with reduced patient survival, few studies have evaluated the incidence of HER-2 overexpression in patients with metastatic breast cancer (MBC) and examined whether increased levels of this protein indicate a poorer prognosis and/or reduced responsiveness to systemic treatment. [14][15][16][17][18][19][20][21][22][23][24] In these studies, 30-50% of patients with MBC had elevated levels of circulating (plasma, serum) extracellular domain of HER-2. [14][15][16][17][18][19] Overexpression correlates with an increased tumour burden and reduced survival.…”

mentioning

confidence: 99%

“…[14][15][16][17][18][19] Overexpression correlates with an increased tumour burden and reduced survival. [14][15][16]18,[22][23][24][25] Since EIA (enzyme immunoassay) is a relatively simple assay commonly used in clinical medicine, the possibility that elevated levels of extracellular HER-2 could indicate poor prognosis in patients with MBC is of particular interest.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

Bewick

Chadderton

Conlon

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:C-erbB-2/HER-2 (designated HER-2) is overexpressed in both primary and metastatic breast cancer and predicts poor prognosis. We investigated the expression of HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy (HDCT) with autologous blood stem cell (ABSC) support and correlated the presence (positive) or absence (negative) of HER-2 overexpression in these patients with response to treatment, progression-free survival (PFS) and overall survival (OS). The level of HER-2 expression was analyzed in 57 patients with metastatic breast cancer undergoing HDCT with ABSC support. Plasma from peripheral blood was taken at three different time points during the course of treatment and was analyzed using an enzyme immunoassay (EIA) to detect circulating levels of the extracellular portion of HER-2. HER-2 levels were elevated (Ͼ0.2 U/mg protein) in 27/57 (47.4%) patients at one or more time points during treatment. The level of HER-2 varied during the course of treatment. Following induction chemotherapy (ICT), five patients who were negative initially, showed overexpression of HER-2. Three patients overexpressed HER-2 only after HDCT/ABSC. Response to treatment was similar in patients independent of plasma HER-2 levels. Overexpression of HER-2 was associated with a significantly shorter PFS (P = 0.004, log rank) and OS (P = 0.003, log rank) after HDCT/ABSC. HER-2 overexpression, patient age, estrogen receptor status, progesterone receptor status, and previous hormone treatment were assessed by univariate and multivariate analysis. Univariate analysis determined that only HER-2 overexpression correlated significantly with decreases in progression free survival (P = 0.005, Cox regression). Decreased overall survival correlated significantly with HER-2 overexpression (P = 0.004) and decreased expression of both estrogen receptor (P = 0.032) and progesterone receptor (P = 0.039). In multivariate analysis of these variables, only HER-2 expression levels proved to be of independent statistical significance in predicting outcome for both PFS (P = 0.007) and OS Correspondence: Dr S Glück, Depts Oncology, Medicine, and Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Tom Baker Cancer Centre, 1331, 29th Street NW, Calgary, Alberta, Canada Received 18 August 1998; accepted 5 May 1999 (P = 0.002). These results suggest that overexpression of HER-2, measured by EIA in plasma may predict a shorter PFS and OS in patients with metastatic breast cancer treated with HDCT and ABSC support.

show abstract

Section: Discussionmentioning

confidence: 66%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

Bewick

Chadderton

Conlon

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In several studies, neu-oncoprotein overexpression in the tumour tissue has been analysed and found to correlate with the elevation of its serum level [17,[36][37][38]. Thus, it seems likely that the source of increased serum neu-oncoprotein in the patients included in these studies is their affected liver tissue [17].…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma

Zekri¹,

Bahnassy

Shaarawy

et al. 2000

Journal of Medical Microbiology

View full text Add to dashboard Cite

The distribution of hepatitis C virus (HCV) genotypes among Egyptian patients positive for anti-HCV was determined and their influence, when combined with neu-oncoprotein overexpression, on the development of hepatocellular carcinoma (HCC) was examined. The study groups included asymptomatic carriers (ASC) and patients with chronic active hepatitis (CAH) and HCC. HCV genomes were detected in the sera of 27 ASC, 29 CAH and 33 HCC patients known to have HCV infection defined by EIA and recombinant immunoblotting techniques (Inno-LiA) as well as by reverse transcriptase (RT)-PCR. The HCV genotype was determined by a reverse hybridisation technique (Inno-LiPA I and II), whereas neu-overexpression was detected by the Oncogene Science EIA Kit. Eighty-nine patients were eligible for HCV genotyping; 75 patients (84.3%) were infected with a single genotype, including 1a in 11 patients (12.4%), 1b in 2 patients (2.2%) and 2a in 10 patients (11.2%). Genotype 4 (a or cþd) was detected in 51 patients (57.3%) and only one patient had genotype 10a (1.2%). Fourteen patients (15.7%) showed mixed infection; eight of them had 1aþ4 (a or cþd) and four had 2aþ4 (a or cþd); the remaining two cases had 1aþ2a and 1bþ2a. The results revealed an increased incidence of genotype 4 in CAH and HCC patients in comparison with ASC. There was also a significant overexpression of neu-oncoprotein in CAH and HCC patients compared with ASC, which was significantly associated with subtype 4 infection. The results suggest that infection with subtype 1a and 4 HCV may be considered a risk factor for the induction of neu-overexpression and subsequent development of HCC.

show abstract

“…The external domain of c-erbB-2 protein is frequently secreted and can be detected in human serum [8][9][10][11]. Elevated c-erbB-2 concentrations have been reported in approximately 5-30% of primary breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer

Fehm¹,

Maimonis

Katalinic

et al. 1997

Oncology

View full text Add to dashboard Cite

The relationship between c-erbB-2 serum positivity and prognosis was evaluated in 80 patients with metastatic breast cancer. Using 120 fmol/ml as a cutoff level, elevated concentrations were found in 31 patients (38.8%) at the time of detection of metastases. Menopausal status, steroid receptor status, site of recurrence, initial tumor size, initial degree of nodal involvement as well as relapse-free interval were unrelated to c-erbB-2 serum positivity. In addition, no association could be found between adjuvant chemotherapy and positive c-erbB-2 concentrations. Patients with elevated c-erbB-2 levels showed a lower response rate (including complete remission, partial remission, no change) to first-line therapy than those with normal levels (29 vs. 59%, p < 0.01). The median survival time after relapse was 12 months (CI: 3–22 months) for the c-erbB-2-negative patients and only 6 months (CI: 3–8 months) for the c-erbB-2-positive group (p < 0.01). In the multivariate analysis, while c-erbB-2 levels at the time of primary surgery had no significant impact on survival in metastatic breast cancer, serum c-erbB-2 turned out to be the strongest factor for predicting survival after relapse.

show abstract

Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients

Cited by 34 publications

References 14 publications

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma

The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer

Contact Info

Product

Resources

About